Industry Appeals India Caps On Key Drug Prices
This article was originally published in PharmAsia News
Drug companies that market in India have appealed to the government to review the decision of its National Pharmaceutical Pricing Authority regarding price caps. Ranbaxy Laboratories and foreign pharmas object to the NPPA's caps on antibiotics, painkillers and erectile dysfunction drugs, as well as other big-selling brand treatments. But before the government agrees to review the caps, it asked some of the protesting firms to comply first, at least with regard to 10 key brands. Only then would the Chemicals and Fertilisers Ministry consider the company complaints. (Click here for more
You may also be interested in...
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
The US FDA’s Circulatory System Devices advisory panel will meet on 27 October to discuss the review of the premarket approval application of Neovasc’s Reducer device, which is intended to treat angina. See what Neovasc’s CEO Fred Colen said about it here.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.